Skip to main content


Log in

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

  • Published:
Investigational New Drugs Aims and scope Submit manuscript


Panobinostat (LBH589) is a potent pan-histone deacetylase inhibitor. As a result of promising preclinical data, Phase I and II clinical trials of intravenous and oral panobinostat have been conducted in patients with a wide variety of hematologic and solid tumors. This is the first report of a phase I study to evaluate intravenous panobinostat given on days 1 and 8 of a 21-day cycle in patients with solid tumors. The primary objective was to characterize the safety and tolerability of panobinostat by evaluating the occurrence of dose-limiting toxicity (DLT) and determining the maximum tolerated dose (MTD) in Japanese patients with advanced solid tumors. Secondary objectives included characterizing the pharmacokinetics and assessing antitumor activity. Fourteen patients were assigned to three dose levels (Cohort 1: 10 mg/m2 [three patients], Cohort 2: 15 mg/m2 [three patients], Cohort 3: 20 mg/m2 [eight patients]), according to a standard “3 + 3” design. One patient who received 20 mg/m2 had a DLT (grade 3 elevation of γ-glutamyl transpeptidase for >7 days). Thrombocytopenia was observed in all patients (grade 3 or 4 in 8), the severity of which was dependent on the dose and platelet count at baseline. The thrombocytopenia rapidly resolved within 8 days. Plasma panobinostat levels increased dose dependently, without clinically significant drug accumulation. Stable disease for ≥4 months was observed in six patients; however, there were no complete or partial responses. It is feasible to conclude that 20 mg/m2 was the MTD and recommend as the starting dose for phase II clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Prince HM, Bishton MJ, Johnstone RW (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601–612

    Article  PubMed  CAS  Google Scholar 

  2. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Lett 280:233–241

    Article  PubMed  CAS  Google Scholar 

  3. Haberland M, Montgimery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature 10:32–42

    CAS  Google Scholar 

  4. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459–5468

    Article  PubMed  CAS  Google Scholar 

  5. Sharma S, Vogelzang NJ, Beck J et al (2007) Phase Ι pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J Clin Oncol 25:613s [abstract 14019]

    Article  Google Scholar 

  6. Giles F, Fischer T, Cortes J et al (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12:4628–4635

    Article  PubMed  CAS  Google Scholar 

  7. Giver CR, Jaye DL, Waller EK, Kaufman JL, Lonial S (2011) Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia 25:362–365

    Article  PubMed  CAS  Google Scholar 

  8. Matsuoka H, Unami A, Fujimura T et al (2007) Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 571:88–96

    Article  PubMed  CAS  Google Scholar 

  9. Bishton MJ, Harrison SJ, Martin BP et al (2011) Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117:3658–3668

    Article  PubMed  CAS  Google Scholar 

  10. Fukutomi A, Hatake K, Matsui K et al (2011) A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs. doi:10.1007/s10637-011-9666-9

  11. Ramalingam SS, Kummar S, Sarantopoulos J et al (2010) Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. J Clin Oncol 28:4507–4512

    Article  PubMed  CAS  Google Scholar 

  12. Nakatani F, Tanaka K, Sakimura R et al (2003) Identification of p21WAF1/CIP1 as a direct target of EWS-Fli 1 oncogenic fusion protein. J Biol Chem 278:15105–15115

    Article  PubMed  CAS  Google Scholar 

  13. Sakimura R, Tanaka K, Nakatani F et al (2005) Antitumor effect of histone deacetylase inhibitor on Ewing’s family tumors. Int J Cancer 116:784–792

    Article  PubMed  CAS  Google Scholar 

  14. Owen LA, Kowalewski AA, Lessnick SL (2008) EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One 3:e1965

    Article  PubMed  Google Scholar 

  15. Richter GHS, Plehm S, Fasan A et al (2009) EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 106:5324–5329

    Article  PubMed  CAS  Google Scholar 

Download references


This study was supported by research funding from Novartis Pharma (study No. CLBH589A1101). Hiromi Tanii and Junko Kimura are employees of Novartis Pharma. The other authors have no conflicts of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Yuichi Ando.

Additional information

This trial is registrated at as NCT00739414.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morita, S., Oizumi, S., Minami, H. et al. Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 30, 1950–1957 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: